Penpulimab plus cetuximab for advanced head and neck cancer
Part of Cancer clinical trials.
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older, and you have squamous cell cancer in the mouth, throat, voice box, or lower throat area
- Your cancer has come back or spread, and doctors don’t think surgery or radiation can control it
- You have at least one measurable tumor spot on scans
- Your tumor must be PD-L1 positive with CPS 1 or higher
- You need to be well enough to do treatment (ECOG performance status 0–1) and expect to live at least 3 months
- Your blood, liver, kidney, and clotting tests must meet safety limits, and you can’t have had blood transfusions within 14 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
Hear when a new Head and Neck Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.